

CADILA

PHARMACEUTICALS

LIMITED

CHEMICALS SBU

Works:

294, G.I.D.C., Estate, Ankleshwar - 393 002.

Gujarat, India.

Phone : +91-2646-251519/252626

Fax : +91 -2646 - 250051 Website : www.cadilapharma.com

Page 1 of 2

Name of Finished Drug s				
Manufactured By.	Cadila Pharmaceutica	Cadila Pharmaceuticals Limited, Ankleshwar		
Batch No.	20FH029	A.R. No.	20FP0180	
Manufacturing Date	FEBRUARY 2020	Qty. Mfgd.	152.28 Kg.	
Expiry Date	JANUARY 2025	Sample Qty.	126.74 gm	
Specification No	FPS/239			
Storage condition			erature. (Not more than 25°C, excursion	
	allowed 15°C to 30°C).			
		ate of Analysis		
Test	Requir	ements	Results	
Characters: A. Description	A. White or almost whi	te crystalline powder.	White crystalline powder.	
B. Solubility	B. Sparingly soluble methylene chloride, methanol.	in water and in Freely soluble in	Sparingly soluble in water and i methylene chloride, Freely soluble i methanol.	
Identification A. By IR  B. Test for chloride	A. The infrared absorp from the sample shou the spectrum obtain Hydrochloride working B. Should be responds	Id be concordant with ed from Fluoxetine standard.	The infrared absorption spectrum obtained from the sample is concordant with the spectrum obtained from Fluoxetine Hydrochloride working standard.	
Appearance of solution	Solution should be clear		Solution clear and colourless	
pl-l	Between 4.5 and 6.5	.4.0	5.95	
Optical rotation	Between – 0.05° and + 0	).05°	-0.00°	
Water content (By KF)	Not more than 0.50 % v		0.04 % w/w	
Sulfated ash	Not more than 0.10 % v		0.04 % w/w	
Related substances (By HPLC)	Not more than 0.10 %	W/W	0.04 /0 W/W	
Impurity A Impurity B Impurity C Dimethyl amine impurity at RR about 1.35 Individual impurity Total impurities	Not more than 0.25 % Not more than 0.25 % Not more than 0.15 % Not more than 0.10 % Not more than 0.10 % Not more than 0.50 %		Not Detected Less than 0.01 % Below Detection limit Not Detected  Below Disregard limit 0.04 %	
Assay (By HPLC)	Not less than 98.0 % w 102.0 % w/w of C <sub>17</sub> H <sub>1</sub> on the anhydrous basis		100.8 % w/w	
Residual solvents (By GC) Benzene Ethyl acetate Toluene *Acetonitrile (By GC)	Not more than 1 ppm Not more than 5000 ppr Not more than 100 ppm Not more than 0.1 %		Not Detected Not Detected Not Detected Not Perfomed	
Additional Test:	more than 0.1 70		1	
Particle size	90 % less than 50 μ.		90 % particles are 22.1 μ	
		anufactured in accordance	with current Good Manufacturing Practices.	
Account he is not used in the	Prepared By	Checked By	Approved By	
Name	Mukesh Solanki	Jayesh Dhanani	Hasmukh Vamja	
Designation	Sr.Officer-QA	Executive-QA	Sr.Manager-QA	
Signature	സ്ത	and	+ 100	
Date	18-02.20	18:02-20	18.02.20	
E/O 1 007/1 4/12 04 19		1000		

F/QA007/14/13.04.18

Sarkhej-Dholka Road, Bhat, Ahmedabad - 382 210, Gujarat, India. CIN

Phone : +91-2718-225001-15 Fax : +91-2718-225039 Website : www.cadilapharma.com

CIN : U24231GJ1991PLC015132





## Works:

294, G.I.D.C., Estate, Ankleshwar - 393 002.

Gujarat, India.

Phone : +91-2646 - 251519 / 252626

: +91 -2646 - 250051 Website: www.cadilapharma.com

Page 2 of 2

			1 uge 2 01 2
Name of Finished Drug	substance: Fluoxetine I	Hydrochloride Ph	.Eur/BP+IH.
Manufactured By.	Cadila Pharmaceuticals Limited, Ankleshwar		
Batch No.	20FH029	A.R. No.	20FP0180
Manufacturing Date	FEBRUARY 2020	Qty. Mfgd.	152.28 Kg.
Expiry Date	JANUARY 2025	Sample Qty.	126.74 gm
Specification No	FPS/239		
Storage condition	Store in a tightly closed allowed 15°C to 30°C).		nperature. (Not more than 25°C, excursion
	Certific	ate of Analysis	

## Limit of Detection (LOD) and Limit of Quantification (LOQ) table:

Name of compound	LOD (%)	LOQ(%)
Impurity A	0.001	0.002
Impurity B	0.001	0.003
Impurity C	0.016	0.046
Dimethyl amine	0.007	0.018
Fluoxetine	0.004	0.012

Name of compound	LOD (ppm )	LOQ (ppm )
Ethyl Acetate	0.495	1.500
Benzene	0.050	0.150
Toluene	0.165	0.500

	Prepared By	Checked By	Approved By
Name	Mukesh Solanki	Jayesh Dhanani	Hasmukh Vamja
Designation	Sr.Officer-QA	Executive-QA	Sr.Manager-QA
Signature	mm	dus	+8'
Date	18-02-20	18.02.20	18.02-20

F/QA007/14/13.04.18

Registered Office: "Cadila Corporate Campus,"

Sarkhej-Dholka Road, Bhat, Ahmedabad - 382 210, Gujarat, India.

Phone : +91-2718-225001-15 : +91-2718-225039 Website: www.cadilapharma.com : U24231GJ1991PLC015132 CIN

The Care Continues...